Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Scemblix® by Novartis shows superior efficacy in a Phase III trial, significantly increasing molecular remission rates for new chronic myeloid leukemia cases
Latest Hotspot
3 min read
Scemblix® by Novartis shows superior efficacy in a Phase III trial, significantly increasing molecular remission rates for new chronic myeloid leukemia cases
13 January 2024
Novartis' Scemblix® outperforms traditional therapy in achieving significant molecular remission in a Phase III study involving newly diagnosed chronic myeloid leukemia patients.
Read →
Exploring the Latest B7-H3 ADC Deal by Hansoh Pharma International Limited: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest B7-H3 ADC Deal by Hansoh Pharma International Limited: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
On Dec 20, 2023, Hansoh Pharma and GSK unveiled an exclusive deal for the ADC new drug HS-20093, a Hansoh innovation.
Read →
Caliway Announces FDA Phase II Trial Approval for Dercum's Syndrome Candidate CBL-514
Latest Hotspot
3 min read
Caliway Announces FDA Phase II Trial Approval for Dercum's Syndrome Candidate CBL-514
13 January 2024
Caliway Reveals US FDA Approval for Phase II Trial Application of CBL-514, a Sham-Controlled Study Aiming to Address Dercum's Syndrome.
Read →
What are adverse events?
"What" Series
2 min read
What are adverse events?
13 January 2024
Adverse event (AE) refers to any adverse event that may occur to the subject in the clinical trial and may be related to the trial treatment and trial treatment.
Read →
UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
Latest Hotspot
3 min read
UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
13 January 2024
UCB has revealed that the European Commission has sanctioned the use of RYSTIGGO (rozanolixizumab) for treating generalized myasthenia gravis in adult patients across Europe.
Read →
Exploring the Latest AGT siRNA Deal by Sanegene Bio (Suzhou): A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest AGT siRNA Deal by Sanegene Bio (Suzhou): A Guide to Rapidly Accessing Transaction Insights
13 January 2024
Innovent Biologics and Sanegene Bio (Suzhou) announced their partnership to co-develop SGB-3908, an siRNA drug targeting AGT for hypertension treatment.
Read →
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
Latest Hotspot
3 min read
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
13 January 2024
OBI Pharma has disclosed that the FDA has given its approval for a Phase 1/2 clinical trial application concerning OBI-992, a TROP2 antibody-drug conjugate.
Read →
Why is it sometimes difficult to enroll subjects?
Knowledge Base
4 min read
Why is it sometimes difficult to enroll subjects?
13 January 2024
The trial protocol should strictly define what subjects can be enrolled (enrollment criteria) and what subjects cannot be enrolled (exclusion criteria).
Read →
AskBio Commences Phase 2 Clinical Study of GenePHIT in Heart Failure Treatment
Latest Hotspot
3 min read
AskBio Commences Phase 2 Clinical Study of GenePHIT in Heart Failure Treatment
13 January 2024
Asklepios BioPharmaceutical, Inc., a wholly-owned subsidiary of Bayer AG, has launched Phase II of the GenePHIT trial to assess the effectiveness of its gene therapy drug AB-1002 (NAN-101) for congestive heart failure.
Read →
An analysis of Lifileucel's R&D progress and its clinical results presented at the 2023 ESMO_IO Annual Meeting
ESMO 2023
4 min read
An analysis of Lifileucel's R&D progress and its clinical results presented at the 2023 ESMO_IO Annual Meeting
13 January 2024
The latest 4-year follow-up data from C-144-01 on lifileucel’s treatment outcomes and patterns of response were reported in 2023 ESMO_IO.
Read →
Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
Latest Hotspot
3 min read
Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
13 January 2024
Sana Biotech Reveals US Regulatory Approval for Experimental Drug SC262, an Engineered Immune-resistant, Targeted CD22 Allo CAR T Cell Treatment, Aimed at Individuals Suffering from Recurring or Resistant Types of B-cell Cancer.
Read →
Where should clinical trial documents be kept?
Knowledge Base
2 min read
Where should clinical trial documents be kept?
13 January 2024
There are no explicit provisions on the storage of test related documents. However, ichgcp stipulates the minimum filing documents - basic documents.
Read →